Results 81 to 90 of about 2,707 (196)
The Prostate, Volume 84, Issue 11, Page 1076-1085, August 2024.Abstract Background Molecular‐based risk classifier tests are increasingly being utilized by urologists and radiation oncologists to guide clinical decision making. The Decipher prostate biopsy test is a 22‐gene RNA biomarker assay designed to predict likelihood of high‐grade disease at radical prostatectomy and risk of metastasis and mortality.
Nancy Y. Greenland +6 more
wiley +1 more source
PSA – biomarker, mis on muutnud eesnäärmehaiguste kliinilist käsitlust [PDF]
, 2009 Prostataspetsiifi line antigeen on enim kasutatav eesnäärmehaiguste marker kliinilises meditsiinis, mille tähtsus prostata biomarkerina avastati 1979. aastal. Oluline on teada, et PSA on eesnäärme-, mitte kasvajaspetsiifi line marker.
Ausmees, Kristo, Žarkovski, Mihhail
core +2 more sources
Research and Reports in Urology, 2017 Yasushi Nakai,1 Nobumichi Tanaka,1 Makito Miyake,1 Shunta Hori,1 Yoshihiro Tatsumi,1,2 Yosuke Morizawa,1 Tomomi Fujii,2 Noboru Konishi,2 Kiyohide Fujimoto1 1Department of Urology, Nara Medical University, 2Department of Pathology, Nara Medical University,
Nakai Y +8 more
doaj
Neoplasia: An International Journal for Oncology Research, 2006 The incidence and mortality of prostate cancer (PCa) vary greatly in different geographic regions, for which lifestyle factors, such as dietary fat intake, have been implicated.
Uddhav P. Kelavkar +3 more
doaj +1 more source
Deciphering epigenetic regulation of enhancers in high‐risk prostate cancer
Genes, Chromosomes and Cancer, Volume 63, Issue 2, February 2024.Abstract Prostate cancer (PCa) is associated with widespread promoter hypermethylation. We hypothesized that aberrant DNA methylation also targets gene enhancers, modulating their activity and contributing to disease etiology. A patient discovery set (n = 37) was used for differential methylation analysis and biomarker identification using the Infinium
A. V. Tuzova +11 more
wiley +1 more source
MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP) [PDF]
, 2011 Background The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis.
Ali S Arbab +8 more
core +1 more source
Molecular complexity of intraductal carcinoma of the prostate
Cancer Medicine, Volume 13, Issue 2, January 2024.Abstract Intraductal carcinoma of the prostate (IDC‐P) is an aggressive subtype of prostate cancer characterized by the growth of tumor cells within the prostate ducts. It is often found alongside invasive carcinoma and is associated with poor prognosis.
Sha Zhu, Nanwei Xu, Hao Zeng
wiley +1 more source
Usefulness of Comparing of Magnetic Resonance Imaging (MRI) Findings Prior to Repeat Biopsy and Negative Initial Biopsy as a Decision-Making Method for Repeat Prostate Biopsy [PDF]
, 2014 We retrospectively reviewed the data from a cohort of 44 patients with one initial negative transrectal ultrasound-guided prostate biopsy who underwent a repeat biopsy from 2006 to 2013.
今村, 正明 +5 more
core
Frontiers in Oncology, 2012 Introduction: 5-alpha reductase inhibitors can reduce the risk of prostate cancer but can be associated with significant side effects. A library of nomograms which predict the risk of clinical endpoints relevant to dutasteride treatment may help ...
Carvell eNguyen +3 more
doaj +1 more source
Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre [PDF]
, 2013 Objective To investigate the clinical and pathological trends over a ten-year period for robotic-assisted laparoscopic prostatectomy (RALP) in a UK regional tertiary referral centre.
Gnanapragasam, Vincent +14 more
core +1 more source